Emotional symptomatology in obese patients treated with fenfluramine and dextroamphetamine.
Emotional sympomatology data on 78 obese females treated for 3 weeks with fenfluramine, dextroamphetamine, or placebo were evaluated. These obese females were shown to be considerably less emotionally disturbed than neurotic females, and similar in emotional symptomatology to other females seeing physicians for nonpsychiatric complaints. Even within these marginally sympatomatic patients, fenfluramine and dextroamphetamine were significantly more effective than placebo in reducing anxious, depressive, and anxious-depressive symptomatology. Fenfluramine was particularly effective in alleviating anxiety in patients who were initially higher in anxiety. Most important, fenfluramine produced significantly greater weight loss than dextroamphetamine in patients with higher levels of anxiety and depression, while dextroamphetamine was an especially effective anorexic in low anxious patients. Differences in initial anxiety and depression, even within relatively normal patients, may well affect results obtained with fenfluramine and dextroamphetamine in the short-term treatment of obesity.
D000328:Adult; D001007:Anxiety / Q000150:complications / Q000188:drug therapy; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D003863:Depression / Q000150:complications / Q000188:drug therapy; D003913:Dextroamphetamine / Q000627:therapeutic use*; D004644:Emotions / Q000187:drug effects*; D005260:Female; D005277:Fenfluramine / Q000627:therapeutic use*; D006801:Humans; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D010919:Placebos; D013997:Time Factors
D010919:Placebos; D005277:Fenfluramine; D003913:Dextroamphetamine